NEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and ...
You recently posted a couple of articles about the respiratory syncytial virus (RSV) vaccine and the benefits versus the ...
It may feel like you are surrounded by sniffles and coughs, but flu season activity is still low in many parts of the U.S.
An expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed seven new medicines for approval this ...
Dec 12 (Reuters) - GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, for all adults above the age of 18, paving ...
According to DataM Intelligence, the Respiratory Syncytial Virus (RSV) Market Size reached USD 1.95 billion in 2024 and is projected to advance to USD 4.54 billion by 2033, expanding at a strong CAGR ...
Research led by the Veterans Affairs Portland Health Care System in Portland, Oregon, found that a single dose of respiratory ...
Improves 2025 expected GAAP operating expenses by $0.7 billion to a range of $5.2 – $5.4 billion Increases 2025 expected year-end cash balance by $0.5 billion – $1 billion to a range of $6.5 – $7.0 ...
Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected revenue range to $1.6 – $2.0 billion Improves 2025 expected GAAP operating ...
Moderna MRNA incurred a loss of 51 cents per share in the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $2.15. In the year-ago period, the company had reported ...
The COVID-19 vaccine maker reported quarterly sales of $1.02 billion, topping the expected $886.54 million. Sales declined 45% to $1.9 billion from a year ago, primarily due to a $847 million, or 47%, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback